Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 3, 2021, Black Diamond Therapeutics, Inc. (the "Company") appointed
Karsten Witt, M.D., the Company's Senior Vice President of Clinical Development,
Interim Chief Medical Officer until a permanent successor is appointed.
Dr. Witt succeeds Rachel Humphrey, M.D., Chief Medical Officer, effective August
4, 2021.
The Company has offered Dr. Humphrey a separation agreement (the "Separation
Agreement") in connection with the termination of her employment pursuant to
which Dr. Humphrey will receive severance pay and benefits in accordance with
her employment agreement and serve as an advisor to the Company until February
28, 2022 (the "Advisory Period"). The Separation Agreement also extends the
exercise period for any vested stock options held by Dr. Humphrey until the
12-month anniversary of the last day of the Advisory Period.
On August 3, 2021, the Company also appointed Elizabeth Buck, Ph.D., the
Company's Co-Founder and Executive Vice President, Discovery & Translational
Sciences, Chief Scientific Officer.
Effective August 11, 2021, Dr. Buck succeeds Christopher Roberts, Ph.D., Chief
Scientific Officer, who notified the Company on July 12, 2021 of his resignation
from the Company to assume the role of chief executive officer at another
company. Dr. Roberts will serve as an advisor to the Company following his
departure.
© Edgar Online, source Glimpses
BLACK DIAMOND THERAPEUTICS, INC. 
